Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
ARDS
COVID-19
Lung infections
SARS-Cov-2
Journal
Respiratory physiology & neurobiology
ISSN: 1878-1519
Titre abrégé: Respir Physiol Neurobiol
Pays: Netherlands
ID NLM: 101140022
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
09
11
2020
revised:
11
02
2021
accepted:
24
02
2021
pubmed:
4
3
2021
medline:
13
4
2021
entrez:
3
3
2021
Statut:
ppublish
Résumé
Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an increase in surface tension, which in turn can lead to alveolar collapse. The use of the pulmonary surfactant seems to be promising as an additional therapy for the treatment of ARDS. COVID-19 causes lung damage and ARDS, so beneficial effects of surfactant therapy in COVID-19-associated ARDS patients are conceivable, especially when applied early in the treatment strategy against pulmonary failure. Because of the robust anti-inflammatory and lung protective efficacy and the current urgent need for lung-supportive therapy, the exogenous pulmonary surfactant could be a valid supportive treatment of COVID-19 pneumonia patients in intensive care units in addition to the current standard of ARDS treatment.
Identifiants
pubmed: 33657448
pii: S1569-9048(21)00030-6
doi: 10.1016/j.resp.2021.103645
pmc: PMC7916525
pii:
doi:
Substances chimiques
Biological Products
0
Peptides, Cyclic
0
Phospholipids
0
Pulmonary Surfactants
0
AP301 peptide
17ZS80333G
poractant alfa
KE3U2023NP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103645Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Front Bioeng Biotechnol. 2020 Sep 25;8:577172
pubmed: 33102461
Expert Rev Respir Med. 2021 May;15(5):597-608
pubmed: 33331197
Annu Rev Physiol. 2003;65:613-42
pubmed: 12517997
BMC Pulm Med. 2019 Jan 9;19(1):9
pubmed: 30626363
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Front Med (Lausanne). 2020 May 22;7:254
pubmed: 32574339
J Cardiothorac Vasc Anesth. 2012 Oct;26(5):849-56
pubmed: 22265270
Med Hypotheses. 2020 Nov;144:110277
pubmed: 33254581
Exp Ther Med. 2017 Sep;14(3):2608-2612
pubmed: 28947918
Respir Med. 2020 Sep;171:106114
pubmed: 32795902
Crit Care. 2012 Nov 22;16(6):238
pubmed: 23171712
Crit Care. 2020 Apr 16;24(1):154
pubmed: 32299472
JAMA Pediatr. 2014 Oct;168(10):901-8
pubmed: 25089718
Drug Des Devel Ther. 2013 Aug 29;7:905-16
pubmed: 24039400
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
Respir Res. 2021 Jan 18;22(1):20
pubmed: 33461535
ACS Nano. 2020 Dec 22;14(12):16502-16524
pubmed: 33236896
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L115-L120
pubmed: 32493030
Respir Res. 2019 Nov 6;20(1):245
pubmed: 31694668
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Exp Ther Med. 2013 Jan;5(1):237-242
pubmed: 23251275
Int J Mol Sci. 2020 Nov 20;21(22):
pubmed: 33233715